InterPAD - DETAILS

2-deoxy-D-glucose, Deoxyglucose, 154-17-6, 2-Deoxy-D-arabino-hexose, 2-Desoxy-D-glucose, 2-DG, (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal, 2-Deoxy-D-mannose, D-2-Deoxyglucose, D-arabino-2-desoxyhexose, D-Arabino-hexose, 2-deoxy-, HSDB 5484, D-Glucose, 2-deoxy-, 9G2MP84A8W, Glucose, 2-deoxy-, 2 Deoxyglucose, MFCD00151328, arabino-Hexose, 2-deoxy-, 2 Deoxy D glucose, 2 Desoxy D glucose, UNII-9G2MP84A8W, 2-Desoxy-D-glucose [French], CCRIS 9094, NSC-15193, EINECS 205-823-0, D-2dGlc, BRN 1723331, 2-DEOXYLGLUCOSE, 2-Deoxy-D-arabino-hexose;D-Arabino-2-deoxyhexose, SCHEMBL7670, 4-01-00-04282 (Beilstein Handbook Reference), CHEMBL2074932, DTXSID1037648, 2-DEOXY-D-GLUCOSE [MI], 2-DEOXY-D-GLUCOSE [HSDB], ALBB-022735, AMY10934, 2-DEOXY-D-GLUCOSE [MART.], 2-DEOXY-D-GLUCOSE [WHO-DD], AKOS015919409, AKOS015924825, DB08831, 2-Deoxy-D-glucose, BioXtra, >=98%, AS-12502, DB-024740, D0051, NS00099319, A26275, D-arabino-Hexose, 2-deoxy- (6CI,8CI,9CI), 2-Deoxy-D-glucose, >=98% (GC), crystalline, 2-Deoxy-D-glucose, >=99% (GC), crystalline, Q3266534, 5CFA0332-FB70-485D-A064-6C4C39E7CBA1, 2-Deoxy-D-glucose, United States Pharmacopeia (USP) Reference Standard

No.	Title	Href
1	Targeting the ROS/PI3K/AKT/HIF-1α/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2-Deoxy-d-glucose. J Cell Mol Med. 2019 May;23(5):3711-3723. doi: 10.1111/jcmm.14276.	`Click`

No.

Title

Href

Targeting the ROS/PI3K/AKT/HIF-1α/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2-Deoxy-d-glucose. J Cell Mol Med. 2019 May;23(5):3711-3723. doi: 10.1111/jcmm.14276.

Click

Name	2-Deoxy-d-glucose
PubChem CID	108223
Molecular Weight	164.16g/mol
Synonyms	2-deoxy-D-glucose, Deoxyglucose, 154-17-6, 2-Deoxy-D-arabino-hexose, 2-Desoxy-D-glucose, 2-DG, (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal, 2-Deoxy-D-mannose, D-2-Deoxyglucose, D-arabino-2-desoxyhexose, D-Arabino-hexose, 2-deoxy-, HSDB 5484, D-Glucose, 2-deoxy-, 9G2MP84A8W, Glucose, 2-deoxy-, 2 Deoxyglucose, MFCD00151328, arabino-Hexose, 2-deoxy-, 2 Deoxy D glucose, 2 Desoxy D glucose, UNII-9G2MP84A8W, 2-Desoxy-D-glucose [French], CCRIS 9094, NSC-15193, EINECS 205-823-0, D-2dGlc, BRN 1723331, 2-DEOXYLGLUCOSE, 2-Deoxy-D-arabino-hexose;D-Arabino-2-deoxyhexose, SCHEMBL7670, 4-01-00-04282 (Beilstein Handbook Reference), CHEMBL2074932, DTXSID1037648, 2-DEOXY-D-GLUCOSE [MI], 2-DEOXY-D-GLUCOSE [HSDB], ALBB-022735, AMY10934, 2-DEOXY-D-GLUCOSE [MART.], 2-DEOXY-D-GLUCOSE [WHO-DD], AKOS015919409, AKOS015924825, DB08831, 2-Deoxy-D-glucose, BioXtra, >=98%, AS-12502, DB-024740, D0051, NS00099319, A26275, D-arabino-Hexose, 2-deoxy- (6CI,8CI,9CI), 2-Deoxy-D-glucose, >=98% (GC), crystalline, 2-Deoxy-D-glucose, >=99% (GC), crystalline, Q3266534, 5CFA0332-FB70-485D-A064-6C4C39E7CBA1, 2-Deoxy-D-glucose, United States Pharmacopeia (USP) Reference Standard
Drug Type	Small molecule
Formula	C₆H₁₂O₅
SMILES	C(C=O)C(C(C(CO)O)O)O
InChI	1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
InChIKey	VRYALKFFQXWPIH-PBXRRBTRSA-N
CAS Number	154-17-6
ChEMBL ID	CHEMBL2074932
TTD ID	D0H3KI
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Polydatin, 2-Deoxy-d-glucose
Partner Name	Polydatin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Inhibition-->Glycolysis
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	HIF1A	hsa3091
	Down-regulation	Expression	HK2	hsa3099
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Up-regulation	Expression	PARP1	hsa142
	Down-regulation	Expression	PIK3CA	hsa5290
	Down-regulation	Expression	ROS1	hsa6098
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vivo Model	Approximately 2.0×10⁷ 4T1 cells without any contamination were harvested and suspended in 100 μL of PBS, then subcutaneously injected into the mouse's fourth breast pad.
Result	Our study demonstrates that PD synergised with 2-DG to enhance its anti-cancer efficacy by inhibiting the ROS/PI3K/AKT/HIF-1α/HK2 signalling axis, providing a potential anti-cancer strategy.